JAMES R. MUSICK
Chairman, President & CEO
Vitro Diagnostics, Inc.4621 Technology DriveGolden, CO 80403
(303) 762-1240 – FAX
SIC Number: 2836
Fiscal Year End: 10-31
Transfer Agent: Securities Transfer Corporation
2591 Dallas Pkwy Ste 102
Frisco, TX 75034
Outstanding Shares: 17,214,000 Public Float: 11.577M
All Share data is up to date Taken from the 10K & 10Q 2008:
In the last 12 years the OS has only been raised 8M shares
The company has been fully reporting since 1996
There has never been a Reverse Split
Nevada Secretary of State:
Copy link into your browser for Authorized Share Info
DISCLAIMER: Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions. There is no express or implied solicitation to buy or sell securities. The author(s) most likely will have positions in the stock, and may/will trade a portion or all of the position in the stock mentioned. Readers are advised to conduct their own due diligence prior to considering buying or selling any stock. All information should be considered for information purposes only. No stock exchange has approved or disapproved of the information
Vitro's cell immortalization patent allowed.
Press Release: Vitro granted additional fertility drug patents.
PAT. NO. 6,414,123
PAT. NO 5,990,288
Vitro Awarded Cell Immortalization Patent By United States Patent Office
PAT. NO 6,458,593
Recent patent Application that the company expects to gain a Notice of Allowance with an issued patent to follow
June 23,2008 Wall Street Transcript interview...
2007 Interview with The Wall Street Transcript
Vitro Diagnostics, Inc. dba, Vitro BioPharma (OTC Bulletin Board; VODG) is a publicly traded biotechnology firm committed to “Harnessing the Power of Cells”. The Company has generated over 30 adult human stem cell lines that drive numerous commercial opportunities in medical research and treatment of disease. Our business plan focuses on initiatives to: 1) commercialize products for use in drug development & discovery, 2) develop and commercialize products to treat animal diabetes and 3) develop and commercialize a stem cell-based treatment of human diabetes. Our advanced stem cell technology has broad application to several high-value medical products. We intend to leverage our platform technology to build a Company based on high-margin products targeting a variety of diverse markets in medical research and treatment of previously untreatable or under-treated diseases.
Informative Links regarding Pancreatic Islet Therapy:
Shortage of Islets: major obstacle to widespread use of islet transplantation is the shortage of islets.
Nearly 600 diabetes patients worldwide have now received islet transplants, and enough patients have been transplanted that long-term benefits can be documented.
Cell Therapies For Diabetes, Cancer May Be Coming Soon
Pancreatic Stem Cell Transplantation
Researchers are a step closer to a cure for type 1 diabetes after the successful transplantation of insulin-producing cells into eight patients.
Cell transplant dramatically changes diabetic's life
Published: Wednesday, 19-Mar-2008
Six centres are receiving nearly £10m of government funding ( London) to offer transplants of insulin-producing cells.
Transplants of own stem cells may let diabetics forgo insulin
In Vivo Imaging of Immune Rejection in Transplanted Pancreatic Islets
SEC EDGAR Filings: Fully reporting for 12 years OS grew by only 8m shares since that time